Audio
Teilen
PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws.
Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or CLICK HERE.
Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Berger Montague's investigation centers on a proposed merger with Novo Nordisk A/S, announced on October 9, 2025, whereby Akero shareholders will receive $54.00 per share in cash and one Contingent Value Right entitling each holder to receive $6.00 per share if Akero's lead product candidate efruxifermin, a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), achieves regulatory approval by June 30, 2031.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Radha Raghavan
Berger Montague
(215) 875-4698
rraghavan@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigates-akero-therapeutics-inc-and-its-board-of-directors-for-breach-of-fiduciary-duties-and-violations-of-federal-securities-laws-nasdaq-akro-302613249.html
SOURCE Berger Montague
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
